V940 2026

Get Form
v940 Preview on Page 1

Here's how it works

01. Edit your form online
Type text, add images, blackout confidential details, add comments, highlights and more.
02. Sign it in a few clicks
Draw your signature, type it, upload its image, or use your mobile device as a signature pad.
03. Share your form with others
Send it via email, link, or fax. You can also download it, export it or print it out.

How to use or fill out v940 with our platform

Form edit decoration
9.5
Ease of Setup
DocHub User Ratings on G2
9.0
Ease of Use
DocHub User Ratings on G2
  1. Click ‘Get Form’ to open the v940 in the editor.
  2. Begin by entering your personal information in the designated fields, including your name, address, and contact details. Ensure accuracy for seamless processing.
  3. Next, navigate to the section that requires specific details about your request. Fill in all necessary fields carefully, as this information is crucial for the form's purpose.
  4. If applicable, review any checkboxes or options provided within the form. Select those that pertain to your situation to ensure clarity in your submission.
  5. Finally, double-check all entries for completeness and correctness before submitting. Utilize our platform’s features to save or print a copy of your completed v940 for your records.

Start using our platform today to fill out your v940 form online for free!

See more v940 versions

We've got more versions of the v940 form. Select the right v940 version from the list and start editing it straight away!
Versions Form popularity Fillable & printable
2019 4.8 Satisfied (181 Votes)
2019 4.2 Satisfied (118 Votes)
2019 4.4 Satisfied (275 Votes)
2014 4.3 Satisfied (52 Votes)
2007 4 Satisfied (58 Votes)
be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.
Contact us
About mRNA-4157 (V940) Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity.
The most common adverse events attributed to mRNA-4157 (V940) in combination with KEYTRUDA were fatigue (60.6%), injection site pain (56.7%), and chills (49.0%). The majority of the adverse events attributed to mRNA-4157 (V940) were Grade 1-2, with fatigue being the most common Grade 3 event and no Grade 4-5 events.
mRNA-4157/V940 is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patients tumor. KEYTRUDA is an immunotherapy that works by increasing the ability of the bodys immune system to help detect and fight tumor cells.
After vaccination, the mRNA will enter the muscle cells. Once inside, they use the cells machinery to produce a harmless piece of what is called the spike protein. The spike protein is found on the surface of the virus that causes COVID-19.
mRNA-4157/V940 is an mRNA based cancer vaccine. When administered, it will produce one of several dozen possible abnormal proteins commonly found in cancerous tissues. The production of those proteins is intended to invoke an immune response.

Security and compliance

At DocHub, your data security is our priority. We follow HIPAA, SOC2, GDPR, and other standards, so you can work on your documents with confidence.

Learn more
ccpa2
pci-dss
gdpr-compliance
hipaa
soc-compliance

People also ask

Safety, tolerability, and immunogenicity were assessed. All patients experienced 1 treatment-emergent adverse event; there were no grade 4/5 adverse events or dose-limiting toxicities. mRNA-4157 alone induced consistent de novo and strengthened preexisting T-cell responses to targeted neoantigens.
Fatal adverse reactions occurred in 8% of patients who received KEYTRUDA including infection (2.3%) and thromboembolism (1.3%). KEYTRUDA was permanently discontinued due to adverse reactions in 15% of patients.

Related links